Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 2020

View Archived Issues

New mouse model of MLL-ENL-driven AML to understand the early stages of leukemogenesis

Discovery of amide-linked benzimidazole-benzoxaborole hybrids for the treatment of onchocerciasis

Caelum initiates phase II study of CAEL-101 in AL amyloidosis

Phase II results for pembrolizumab in patients with advanced rare cancers

miR15a-1 as a new a noninvasive biomarker for asthma

Sepsis study may yield new treatment strategies

Dead cells do tell tales

TET1 gene therapy patented by the Military Medical Institute Academy

How lung tumors seed to brain

Roche synthesizes new TLR7/TLR8/TLR9 antagonists

Medshine Discovery discovers drugs targeting protein cereblon

New geranylgeranyl transferase type 1 inhibitors identified at Bayer

Abbisko Therapeutics identifies new fibroblast growth factor receptor inhibitors

Investigators describe biomarkers of liver injury

Gimsilumab completes phase I study in development of gimsilumab for COVID-19-related ARDS

NGM studies NGM-395 in obese adults and patients with NAFLD

New Chinese phase I study evaluates Ad5-nCoV coronavirus vaccine

Lundbeck discontinues foliglurax program in Parkinson's following phase IIa results

FDA approves new intravenous formulation of Triferic

Lundbeck reports phase IIa results with Lu-AG06466 in Tourette's syndrome

FDA approves Imfinzi as first-line treatment for extensive-stage SCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...